I think licensing in the long-run would by far have the greater return for investors, but investors are impatient. Just think of all the licenses they could issue...one for each of half of the known cancers? The company would get license agreement payments, milestone payments and part of the revenue generated etc. There would healthy dividends and massive market appreciation. In my opinion its hard to pick small-cap stocks, if you find a good one hang on to it, so I like this scenario.
But I cannot see it happening. The biggest investors are the ones that have the yes/no on any deal and are set to sell when the price is right, in my opinion. Do they really want to manage a full-fledged company? How old is Dr. Menon? I am also guessing Dr. Menon is more interested in the science than management of a large co.
Its small but its a start..I bet we will see more on the next quarterly report..sorry if this is rehash
No science talk... just free market capitalism here. I hear buyout, buyout, buyout when it comes time for big pharma (Roche, Pfizer, Celgene, whoever) to play Let's Make a Deal. With a significant pipeline for a small cap biotech, wouldn't licensing each product individually produce a better return? I don't believe fellow shareholders Leo or Dr Menon would hand over the keys to a company looking for a quantity discount.
Market Data 
Markets 
AI
